You are here

  • Home
  • Archive
  • Volume 10, Issue 1
  • Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses

 

Online download statistics by month:

Online download statistics by month: January 2022 to September 2024

AbstractFullPdf
Jan 2022798819223
Feb 2022624647198
Mar 2022456466168
Apr 2022341346147
May 2022283292116
Jun 2022386400123
Jul 202226226795
Aug 2022300306125
Sep 2022280290157
Oct 2022305325133
Nov 2022352353149
Dec 202222823085
Jan 202319220597
Feb 202320621083
Mar 2023210212101
Apr 202314314474
May 202320020189
Jun 202316416866
Jul 202314514685
Aug 202315615859
Sep 202315715990
Oct 202317017190
Nov 202317918261
Dec 202315916078
Jan 202413013068
Feb 202413613756
Mar 202419019480
Apr 202420720883
May 202413013461
Jun 202412512566
Jul 202415215478
Aug 2024838435
Sep 2024133134123
Total798281573342